Amyris (NASDAQ:AMRS – Get Rating) was downgraded by equities research analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat Ratings reports.
A number of other research firms also recently issued reports on AMRS. Roth Capital downgraded shares of Amyris from a “buy” rating to a “neutral” rating in a report on Wednesday, August 10th. Piper Sandler raised their price objective on shares of Amyris from $2.50 to $4.00 and gave the stock a “neutral” rating in a report on Monday, September 19th. Two investment analysts have rated the stock with a sell rating and three have given a hold rating to the company. According to MarketBeat.com, Amyris has a consensus rating of “Hold” and a consensus price target of $5.33.
Amyris Stock Up 21.5 %
Shares of NASDAQ AMRS opened at $1.84 on Wednesday. The firm’s 50-day moving average price is $2.93 and its 200-day moving average price is $2.62. The company has a market cap of $595.13 million, a PE ratio of -1.06 and a beta of 1.22. Amyris has a 52-week low of $1.44 and a 52-week high of $8.16.
Insiders Place Their Bets
In other Amyris news, Director Frank Kung sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $3.50, for a total transaction of $700,000.00. Following the sale, the director now owns 80,000 shares in the company, valued at approximately $280,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 2,665,676 shares of company stock worth $10,623,569. Company insiders own 33.80% of the company’s stock.
Institutional Investors Weigh In On Amyris
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRS. Daiwa Securities Group Inc. raised its position in shares of Amyris by 11.1% during the first quarter. Daiwa Securities Group Inc. now owns 250,000 shares of the biotechnology company’s stock valued at $1,090,000 after buying an additional 25,000 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Amyris by 55.9% in the first quarter. Farallon Capital Management LLC now owns 16,931,427 shares of the biotechnology company’s stock valued at $73,821,000 after purchasing an additional 6,071,616 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Amyris in the first quarter valued at $1,643,000. Nicholas Hoffman & Company LLC. grew its holdings in shares of Amyris by 25.0% in the first quarter. Nicholas Hoffman & Company LLC. now owns 100,000 shares of the biotechnology company’s stock valued at $436,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC grew its holdings in shares of Amyris by 37.8% in the first quarter. Essex Investment Management Co. LLC now owns 359,073 shares of the biotechnology company’s stock valued at $1,566,000 after purchasing an additional 98,549 shares in the last quarter. Institutional investors own 43.08% of the company’s stock.
Amyris Company Profile
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Coupang Stock And Why You Should Care
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.